Domperidone for the symptomatic treatment of chronic post-prandial nausea and vomiting.
Forty patients with postprandial nausea and vomiting from a variety of underlying causes, were given either domperidone 20 mg t.d.s. or placebo in a double-blind study lasting two weeks. The tablets were taken before meals and no other anti-emetics were used. Nausea and vomiting were reduced in those patients given the active therapy, the results being recorded as excellent in 62% in the domperidone group and 18% of controls.
D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004415:Dyspepsia / Q000188:drug therapy; D005260:Female; D005502:Food; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000188:drug therapy*; D010880:Piperidines / Q000627:therapeutic use*; D014839:Vomiting / Q000188:drug therapy*
D000932:Antiemetics; D001562:Benzimidazoles; D010880:Piperidines